PHARMACENTRIC_LIMITED - Accounts

Company registration number 05964690 (England and Wales)
PHARMACENTRIC LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2022
PAGES FOR FILING WITH REGISTRAR
PHARMACENTRIC LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Notes to the financial statements
3 - 7
PHARMACENTRIC LIMITED
BALANCE SHEET
AS AT
31 OCTOBER 2022
31 October 2022
- 1 -
2022
2021
Notes
£
£
£
£
Fixed assets
Intangible assets
4
486,667
20,000
Tangible assets
5
45,991
23,885
532,658
43,885
Current assets
Stocks
96,185
60,187
Debtors
6
264,232
193,023
Cash at bank and in hand
180,315
471,963
540,732
725,173
Creditors: amounts falling due within one year
7
(744,236)
(453,575)
Net current (liabilities)/assets
(203,504)
271,598
Total assets less current liabilities
329,154
315,483
Creditors: amounts falling due after more than one year
8
(28,993)
(38,726)
Provisions for liabilities
(8,738)
(4,538)
Net assets
291,423
272,219
Capital and reserves
Called up share capital
100
100
Profit and loss reserves
291,323
272,119
Total equity
291,423
272,219

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 October 2022 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

PHARMACENTRIC LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 OCTOBER 2022
31 October 2022
- 2 -
The financial statements were approved and signed by the director and authorised for issue on 22 March 2023
Mr Hitesh Dodhia
Director
Company Registration No. 05964690
PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 OCTOBER 2022
- 3 -
1
Accounting policies
Company information

Pharmacentric Limited is a private company limited by shares incorporated in England and Wales. The registered office is Elthorne Gate, 64 High Street, Pinner, Middlesex, HA5 5QA.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, [modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value]. The principal accounting policies adopted are set out below.

1.2
Turnover

Turnover represents revenue generated from the pharmacy and is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT and other sales related taxes. The fair value of consideration takes into account trade discount, settlement discounts and volume rebates.

1.3
Intangible fixed assets - goodwill

Positive goodwill is capitalised, classified as an asset on the balance sheet and amortised on a straight line basis over its useful economic life. It is reviewed for impairment at the end of the first full financial year following the acquisition and in other periods if events or changes in circumstances indicate that the carrying value may not be recoverable.

 

Goodwill, being the amount paid in connection with the acquisition of a business in 2008 and new acquisition of a business in 2021, is being amortised evenly at 15 years in straight line basis.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Leasehold land and buildings
No depreciation charge
Fixtures and fittings
20% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

1.5
Stocks

Stock are valued at the lower of cost and net realisable value, after making due allowance for obsolete and slow moving items.

PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2022
1
Accounting policies
(Continued)
- 4 -
1.6
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.7
Retirement benefits

The company operates a defined contribution pension scheme. Contributions payable to the company's pension scheme are charged to profit or loss in the period to which they relate.

1.8
Government grants

Government grants are recognised at the fair value of the asset received or receivable when there is reasonable assurance that the grant conditions will be met and the grants will be received.

 

A grant that specifies performance conditions is recognised in income when the performance conditions are met. Where a grant does not specify performance conditions it is recognised in income when the proceeds are received or receivable. A grant received before the recognition criteria are satisfied is recognised as a liability.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was:

2022
2021
Number
Number
Total
10
7
PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2022
- 5 -
3
Taxation
2022
2021
£
£
Current tax
UK corporation tax on profits for the current period
20,180
39,302
Deferred tax
Origination and reversal of timing differences
4,200
(676)
Total tax charge
24,380
38,626
4
Intangible fixed assets
Goodwill
£
Cost
At 1 November 2021
240,000
Additions
517,143
At 31 October 2022
757,143
Amortisation and impairment
At 1 November 2021
220,000
Amortisation charged for the year
50,476
At 31 October 2022
270,476
Carrying amount
At 31 October 2022
486,667
At 31 October 2021
20,000
PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2022
- 6 -
5
Tangible fixed assets
Leasehold land and buildings
Fixtures and fittings
Total
£
£
£
Cost
At 1 November 2021
-
0
126,224
126,224
Additions
1
33,603
33,604
At 31 October 2022
1
159,827
159,828
Depreciation and impairment
At 1 November 2021
-
0
102,339
102,339
Depreciation charged in the year
-
0
11,498
11,498
At 31 October 2022
-
0
113,837
113,837
Carrying amount
At 31 October 2022
1
45,990
45,991
At 31 October 2021
-
0
23,885
23,885
6
Debtors
2022
2021
Amounts falling due within one year:
£
£
Trade debtors
182,594
173,671
Other debtors
81,638
19,352
264,232
193,023
7
Creditors: amounts falling due within one year
2022
2021
£
£
Bank loans
11,007
11,274
Trade creditors
301,764
146,257
Taxation and social security
26,980
39,537
Other creditors
404,485
256,507
744,236
453,575
PHARMACENTRIC LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 OCTOBER 2022
- 7 -
8
Creditors: amounts falling due after more than one year
2022
2021
Notes
£
£
Bank loans and overdrafts
9
28,993
38,726
9
Loans and overdrafts
2022
2021
£
£
Bank loans
40,000
50,000
Payable within one year
11,007
11,274
Payable after one year
28,993
38,726

 

 

2022-10-312021-11-01false22 March 2023CCH SoftwareCCH Accounts Production 2023.100No description of principal activityMr Hitesh Dodhia059646902021-11-012022-10-31059646902022-10-31059646902021-10-3105964690core:NetGoodwill2022-10-3105964690core:NetGoodwill2021-10-3105964690core:LandBuildingscore:LeasedAssetsHeldAsLessee2022-10-3105964690core:FurnitureFittings2022-10-3105964690core:LandBuildingscore:LeasedAssetsHeldAsLessee2021-10-3105964690core:FurnitureFittings2021-10-3105964690core:CurrentFinancialInstrumentscore:WithinOneYear2022-10-3105964690core:CurrentFinancialInstrumentscore:WithinOneYear2021-10-3105964690core:Non-currentFinancialInstrumentscore:AfterOneYear2022-10-3105964690core:Non-currentFinancialInstrumentscore:AfterOneYear2021-10-3105964690core:CurrentFinancialInstruments2022-10-3105964690core:CurrentFinancialInstruments2021-10-3105964690core:ShareCapital2022-10-3105964690core:ShareCapital2021-10-3105964690core:RetainedEarningsAccumulatedLosses2022-10-3105964690core:RetainedEarningsAccumulatedLosses2021-10-3105964690bus:Director12021-11-012022-10-3105964690core:Goodwill2021-11-012022-10-3105964690core:LandBuildingscore:LongLeaseholdAssets2021-11-012022-10-3105964690core:FurnitureFittings2021-11-012022-10-31059646902020-11-012021-10-3105964690core:UKTax2021-11-012022-10-3105964690core:UKTax2020-11-012021-10-3105964690core:NetGoodwill2021-10-3105964690core:NetGoodwill2021-11-012022-10-3105964690core:LandBuildingscore:LeasedAssetsHeldAsLessee2021-10-3105964690core:FurnitureFittings2021-10-31059646902021-10-3105964690core:LandBuildingscore:LeasedAssetsHeldAsLessee2021-11-012022-10-3105964690core:WithinOneYear2022-10-3105964690core:WithinOneYear2021-10-3105964690core:Non-currentFinancialInstruments2022-10-3105964690core:Non-currentFinancialInstruments2021-10-3105964690bus:PrivateLimitedCompanyLtd2021-11-012022-10-3105964690bus:SmallCompaniesRegimeForAccounts2021-11-012022-10-3105964690bus:FRS1022021-11-012022-10-3105964690bus:AuditExemptWithAccountantsReport2021-11-012022-10-3105964690bus:FullAccounts2021-11-012022-10-31xbrli:purexbrli:sharesiso4217:GBP